Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P11277
UPID:
SPTB1_HUMAN
Alternative names:
Beta-I spectrin
Alternative UPACC:
P11277; Q15510; Q15519
Background:
The Spectrin beta chain, erythrocytic, also known as Beta-I spectrin, plays a pivotal role in maintaining the structural integrity and stability of erythrocyte plasma membranes. It is a key component of the cytoskeletal network, interacting with band 4.1 and actin to support the erythrocyte's biconcave shape.
Therapeutic significance:
Mutations in the Spectrin beta chain are linked to Elliptocytosis 3 and Spherocytosis 2, hematologic disorders characterized by abnormal erythrocyte shapes leading to hemolytic anemia. Understanding the role of Spectrin beta chain, erythrocytic could open doors to potential therapeutic strategies for these conditions.